# EDGAR Filing Document

**Accession Number:** 0001933567
**File Stem:** 0000000000-23-000780
**Filing Date:** 2023-1
**Character Count:** 5791
**Document Hash:** 47c620ac3fe1fa81ff843e03c4fed92c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000780.hdr.sgml**: 20230906

**ACCESSION NUMBER**: 0000000000-23-000780

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230124

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neuraxis, INC
- **CENTRAL INDEX KEY:** 0001933567
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **IRS NUMBER:** 455079684
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 11550 N. MERIDIAN STREET
- **STREET 2:** SUITE 325
- **CITY:** CARMEL
- **STATE:** IN
- **ZIP:** 46032
- **BUSINESS PHONE:** (812) 689-0791

**MAIL ADDRESS:**
- **STREET 1:** 11550 N. MERIDIAN STREET
- **STREET 2:** SUITE 325
- **CITY:** CARMEL
- **STATE:** IN
- **ZIP:** 46032
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-22-026904

## Text-Extract

```

United States securities and exchange commission logo

                           January 24, 2023

       Brian Carrico
       Chief Executive Officer
       Neuraxis, Inc.
       11550 N. Meridian Street, Suite 325
       Carmel, IN 46032

                                                        Re: Neuraxis, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed January 10,
2023
                                                            File No. 333-269179

       Dear Brian Carrico:

                                                        We have reviewed your
registration statement and have the following comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Registration Statement on Form S-1 filed January 10, 2023

       Prospectus Summary
       Pipeline Table, page 1

   1.                                                   We note your response
to our prior comment and the revised pipeline table on pages 1 and
                                                        54. Please further
revise the table to clearly depict both the discovery and preclinical
                                                        research/non-human
testing phases prior to the Human Clinical Trials column, revising
                                                        the progress arrows as
appropriate
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.

              Refer to Rules 460 and 461 regarding requests for acceleration.
Please allow adequate
       time for us to review any amendment prior to the requested effective
date of the registration
 Brian Carrico
Neuraxis, Inc.
January 24, 2023
Page 2

statement.

       Please contact Cindy Polynice at 202-551-8707 or Laura Crotty at
202-551-7614 with
any other questions.

                                                         Sincerely,
FirstName LastNameBrian Carrico
                                                         Division of
Corporation Finance
Comapany NameNeuraxis, Inc.
                                                         Office of Life
Sciences
January 24, 2023 Page 2
cc:       Tom Twedt
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 24, 2023

Brian Carrico  
Chief Executive Officer  
Neuraxis, Inc.  
11550 N. Meridian Street, Suite 325  
Carmel, IN 46032

**Re: Neuraxis, Inc.  
Registration Statement on Form S-1  
Filed January 10, 2023  
File No. 333-269179**

Dear Brian Carrico:

We have reviewed your registration statement and have the following comment.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments.

Registration Statement on Form S-1 filed January 10, 2023

Prospectus Summary

Pipeline Table, page 1

1. We note your response to our prior comment and the revised pipeline table on pages 1 and 54. Please further revise the table to clearly depict both the discovery and preclinical research/non-human testing phases prior to the Human Clinical Trials column, revising the progress arrows as appropriate

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration

Brian Carrico
Neuraxis, Inc.
January 24, 2023
Page 2

statement.

Please contact Cindy Polynice at 202-551-8707 or Laura Crotty at 202-551-7614 with
any other questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Tom Twedt